Takeda has published results from its Phase 3 clinical trials for Zasocitinib, an oral treatment for moderate-to-severe plaque psoriasis.

• Clinical Results: Data indicate that the once-daily pill met primary endpoints for skin clearance compared to placebo.
• Mechanism: Zasocitinib acts as a selective TYK2 inhibitor, targeting specific inflammatory pathways.
• Regulatory Path: The results will support global regulatory submissions for the treatment of autoimmune skin conditions. 

This summary is based on a press release issued by Takeda.